News from avaxia biologics, inc

Nov 27, 2012, 05:00 ET

Avaxia Biologics Receives IND Clearance from FDA to Initiate Clinical Program to Evaluate AVX-470 as Therapy for Ulcerative Colitis

 Avaxia Biologics, Inc., a privately-held biotechnology company developing oral antibody drugs that act locally within the digestive tract,...

Sep 18, 2012, 05:00 ET

Avaxia Biologics is Awarded U.S. Patent for Antibody Therapy for Modulating Function of Intestinal Receptors and Methods of Treating Diabetes and Obesity

 Avaxia Biologics, Inc., a privately-held biotechnology company developing oral antibody drugs that act locally within the digestive tract,...

Jun 12, 2012, 13:23 ET

Avaxia Biologics Announces Appointment of Michael D. Rivard as VP Corporate Development

 Avaxia Biologics, Inc., a privately-held biotechnology company developing oral antibody drugs, announced today that Michael D. Rivard has...

May 22, 2012, 13:56 ET

Avaxia Biologics is Awarded U.S. Patent for Method to Treat Radiation Damage to the Digestive Tract and Mucositis Caused by Radiation

 Avaxia Biologics, Inc., a privately-held biotechnology company developing oral antibody drugs that act locally within the gastrointestinal...

Apr 26, 2012, 10:00 ET

Avaxia Biologics Elects Christopher Kiritsy to its Board of Directors

 Avaxia Biologics, Inc., a privately-held biotech company using its proprietary platform technology to develop orally-active antibody...

Mar 19, 2012, 10:00 ET

Avaxia Biologics Awarded $1.5 Million Phase II SBIR Grant from NIH to Develop Oral Antibody Therapeutic for Inflammatory Bowel Disease

Avaxia Biologics, Inc., a privately-held biotech company using its proprietary platform technology to develop orally-active antibody therapeutics...

Mar 01, 2012, 10:00 ET

Avaxia Biologic's Barbara Fox Named one of Mass High Tech's Women to Watch in 2012

 Avaxia Biologics, Inc., a privately-held biotech company using its proprietary platform technology to develop orally-active antibody...

Feb 14, 2012, 10:00 ET

Avaxia Biologics, Inc. Closes $4.1 Million Series A Financing to Advance Oral Antibodies for Inflammatory Bowel Disease

Avaxia Biologics, Inc., a privately-held biotech company developing oral antibody drugs that act locally within the gastrointestinal tract,...

Dec 13, 2011, 10:00 ET

Avaxia Biologics is Awarded Patent for its Proprietary Orally Active Antibody for Celiac Disease

 Avaxia Biologics, Inc., a privately-held biotech company developing oral antibody drugs that act locally within the gastrointestinal...

Nov 10, 2011, 08:00 ET

Avaxia Biologics, Inc. Raises $2.2 Million in First Closing of Series A Financing to Advance Oral Antibodies for Inflammatory Bowel Disease

Avaxia Biologics, Inc., a privately-held biotech company developing oral antibody drugs that act locally within the gastrointestinal tract,...

Aug 03, 2011, 09:02 ET

Avaxia Biologics, Inc. Awarded BARDA Contract for Therapeutic Countermeasure to Help the Nation Respond to a Radiological Emergency

Avaxia Biologics, Inc., a privately-held biotech company developing oral antibody drugs that act locally within the gastrointestinal tract,...

Mar 10, 2011, 10:00 ET

Avaxia Biologics Awarded Phase I SBIR Grant to Develop Oral Antibody Therapeutic for Celiac Disease

Avaxia Biologics, Inc., a privately-held biotech company using its proprietary platform technology to develop orally-active antibody therapeutics...

Jan 05, 2011, 10:15 ET

Avaxia Biologics, Inc. to Present Key Pre-Clinical Inflammatory Bowel Disease Remission Data at Biotech Showcase 2011

Avaxia Biologics, Inc., a privately-held biotech company developing an innovative platform technology to deliver orally-active antibodies to the...

Sep 16, 2009, 09:55 ET

Avaxia Biologics Awarded Phase I SBIR Grant to Develop Antibody Therapeutic for Oral Mucositis

Collaboration with Biomodels facilitates development of novel drug product Avaxia Biologics, Inc., a biotechnology company developing oral...

Organizations in the News

The organizations with the most activity in PR Newswire's News Room

ReportBuyer
Research and Markets
Investor-Edge